Skip to Main Content

Samantha Budd Haeberlein, the Biogen senior executive who supervised the development and controversial approval of the Alzheimer’s treatment Aduhelm, has left the company, STAT has learned.

Budd Haeberlein’s employment at Biogen ended on Friday, according to two former Biogen employees with knowledge of the situation. Her departure was characterized as voluntary, coinciding with the desire of Chris Viehbacher, Biogen’s new CEO, to shake up the company’s executive ranks after Aduhelm’s costly commercial failure.

advertisement

“Over more than eight years at Biogen, Samantha made many important scientific contributions to the neurodegeneration field — most notably the advancement of our Alzheimer’s disease pipeline and the development of Aduhelm,” said a Biogen spokesperson, confirming Budd Haeberlein’s departure. “We wish her the best in her future endeavors.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.